Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Scinopharm Aims To Launch Drug In China
by Jean-François Tremblay
November 17, 2014
| A version of this story appeared in
Volume 92, Issue 46
ScinoPharm, a Taiwanese pharmaceutical chemical maker, will work with Nanjing King-friend Biochemical Pharmaceutical to launch a version of regadenoson in China. Sold in the U.S. by Astellas Pharma as Lexiscan, regadenoson is used in stress tests of patients who can’t undergo exercise-based stress. ScinoPharm will develop and produce the active ingredient for regadenoson and King-friend will manage the sterile-injection product and regulatory applications. The companies see a potential market in China of up to $50 million per year.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X